Alahdab M Tarek, Mansour Ibrahim N, Napan Sirikarn, Stamos Thomas D
Division of Cardiology, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL, USA.
J Card Fail. 2009 Mar;15(2):130-5. doi: 10.1016/j.cardfail.2008.10.006. Epub 2008 Dec 5.
The prognostic value of the 6-minute walk test (6MWT) has been described in patients with heart failure (HF); however, limited data are available in an African-American (AA) population. We prospectively evaluated the usefulness of the 6MWT in predicting mortality and HF rehospitalization in AA patients with acute decompensated HF.
Two hundred AA patients (63.1% men, mean age 55.7 +/- 12.9 years) with acute decompensated HF were prospectively studied. Patients were followed to assess 40-month all-cause mortality and 18-month HF rehospitalization. The median distance walked on the 6MWT was 213 m. Of the 198 patients with available mortality data, 59 patients (29.8%) died. Of the 191 patients with available rehospitalization data, 114 (59.7%) were rehospitalized for worsening HF. For patients who walked <or=200 m during the 6MWT, mortality was 41% compared with 19% in patients who walked >200 m (P = .001). For patients who walked <or=200 m during the 6MWT, HF rehospitalization was 68% compared with 52% in those who walked >200 m (P = .027). Multivariate Cox regression analysis showed that 6MWT distance <or=200 m was the strongest predictor of mortality (adjusted hazard ratio [HR], 2.14; confidence interval [CI], 1.20 to 3.81; P = .01) and HF rehospitalization (adjusted HR, 1.62; CI, 1.10 to 2.39; P = .015).
In AA patients hospitalized with acute decompensated HF, 6MWT strongly and independently predicts long-term all-cause mortality and HF rehospitalization.
6分钟步行试验(6MWT)对心力衰竭(HF)患者的预后价值已有描述;然而,关于非裔美国人(AA)群体的数据有限。我们前瞻性评估了6MWT对AA急性失代偿性HF患者死亡率和HF再住院的预测作用。
前瞻性研究了200例AA急性失代偿性HF患者(男性占63.1%,平均年龄55.7±12.9岁)。随访患者以评估40个月的全因死亡率和18个月的HF再住院情况。6MWT的中位步行距离为213米。在198例有可用死亡率数据的患者中,59例(29.8%)死亡。在191例有可用再住院数据的患者中,114例(59.7%)因HF恶化再次住院。6MWT期间步行≤200米的患者死亡率为41%,而步行>200米的患者死亡率为19%(P = .001)。6MWT期间步行≤200米的患者HF再住院率为68%,而步行>200米的患者为52%(P = .027)。多变量Cox回归分析显示,6MWT距离≤200米是死亡率(调整后风险比[HR],2.14;置信区间[CI],1.20至3.81;P = .01)和HF再住院(调整后HR,1.62;CI,1.10至2.39;P = .015)的最强预测因素。
在因急性失代偿性HF住院的AA患者中,6MWT能强有力且独立地预测长期全因死亡率和HF再住院情况。